Biotech Deals by the Numbers
Big pharma-biotech dealmaking continues to increase in popularity and price--companies with later-stage products are finding they truly can drive better deals. Meanwhile, drug companies are increasingly paying for their dealmaking with equity, as they leverage their balance sheet to offset research expenses.
You may also be interested in...
We revisit a chart from 1997 examining deal volume by clinical phase to highlight the changing landscape of late stage licensing.
Wave’s Duchenne muscular dystrophy drug and Lilly’s chronic pain R&D will test the agency’s CID meeting pilot program, while FDA issues draft guidance that highlights potential uses for complex innovative trial designs.